Antisense - Time to shoot the messenger

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 495-503

  Kuss, B ^a   Cotter, F ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Antisense; Apoptosis; bcl 2; Leukaemia; Lymphoma; Phase I

Indexed keywords

COMPLEMENTARY RNA; MESSENGER RNA; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2; PROTEIN KINASE C; RAF PROTEIN;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOWN REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; LEUKEMIA; METABOLISM; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0033014295     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026416314887     Document Type: Review

References (57)

1. Zamecnik P. Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev 1997; 7 (3): 199-202.
2. Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 1998; 8 (2): 115-22.
3. Itaya M, Kondo K. Molecular cloning of a ribonuclease H (RNase HI) gene from an extreme thermophile Thermus thermophilus HB8: A thermostable RNase H can functionally replace the Escherichia coli enzyme in vivo. Nucleic Acids Res 1991; 19 (16): 4443-9.
4. Crooke ST, Lemonidis KM, Neilson L et al. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J 1995; 312 (Pt 2): 599-608.
5. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 1049 (2): 99-125.
6. Monia BP, Johnston JF, Ecker DJ et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992; 267 (28): 19954-62.
7. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays (see comments). Nat Biotechnol 1997; 15 (6): 537-41.
8. Reed JC, Stein C, Subasinghe C et al. Antisense-mediated inhibition of bcl-2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990; 50 (20): 6565-70.
9. Cotter FE, Johnson P, Hall P et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9 (10): 3049-55.
10. Bacon TA, Wickstrom E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region. Oncogene Res 1991; 6 (1): 13-9.
11. Daaka Y, Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 1990; 5 (4): 267-75.
12. Goodchild J, Agrawal S, Civeira MP et at. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides (published erratum appears in Proc Natl Acad Sci USA 1989; 86 (5): 1504). Proc Natl Acad Sci USA 1988; 85 (15): 5507-11.
13. Szczylik C, Skorski T, Nicolaides NC et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253 (5019): 562-5.
14. Eder PS, DeVine RJ, Dagle JM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1991; 1 (2): 141-51.
15. Temsamani J, Tang JY, Padmapriya A et al. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev 1993; 3 (3): 277-84.
16. Temsamani J, Kubert M, Tang J et al. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev 1994; 4 (1): 35-42.
17. Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 1998; 8 (2): 115-22.
18. Stein CA. Does antisense exist? (see comments). Nature Med 1995; 1 (11): 1119-21.
19. Ghosh M, Ghosh K, Cohen JS. Oligodeoxynucleotide analogs as informational drugs to regulate translation. Nucleic Acids Symp Ser 1991; 24: 139-42.
20. Dean NM, Griffey RH. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1997; 7 (3): 229-33.
21. Agrawal S, Jiang Z, Zhao Q et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997; 94 (6): 2620-5.
22. Geary RS, Leeds JM, Henry SP et al. Antisense oligonucleotide inhibitors for the treatment of cancer. 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997; 12 (5): 383-93.
23. Henry SP, Monteith D, Bennett F, Levin AA. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase. Anticancer Drug Des 1997; 12 (5): 409-20.
24. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991; 88 (17): 7595-9.
25. Raynaud FI, Orr RM, Goddard PM et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997; 281 (1): 420-7.
26. Cossum PA, Sasmor H, Dellinger D et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993; 267 (3): 1181-90.
27. Webb A, Cunningham D, Cotter F et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349 (9059): 1137-41.
28. Bishop MR, Iversen PL, Bayever E et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies (see comments). J Clin Oncol 1996; 14 (4): 1320-6.
29. Bishop MR, Iversen PL, Bayever E et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies (see comments). J Clin Oncol 1996; 14 (4): 1320-6.
30. Calabretta B, Skorski T, Ratajczak MZ, Gewirtz AM. Antisense strategies in the treatment of leukemias. Semin Oncol 1996; 23 (1): 78-87.
31. Glover JM, Leeds JM, Mant TG et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282 (3): 1173-80.
32. Stein CA. How to design an antisense oligodeoxynucleotide experiment: A consensus approach. Antisense Nucleic Acid Drug Dev 1998; 8 (2): 129-32.
33. Wang W, Chen HJ, Sun J et al. A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation. Antisense Nucleic Acid Drug Dev 1998; 8 (3): 227-36.
34. Cowsert LM. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development. Anticancer Drug Des 1997; 12 (5): 359-71.
35. Vaughn JP, Iglehart JD, Demirdji S et al. Antisense DNA down-regulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 1995; 92 (18): 8338-42.
36. Citro G, Szczylik C, Ginobbi P et al. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer 1994; 69 (3): 463-7.
37. Tortora G, Caputo R, Damiano V et al. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. Antisense Nucleic Acid Drug Dev 1998; 8 (2): 141-5.
38. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 107-29.
39. Crooke ST. Progress in antisense therapeutics. Med Res Rev 1996; 16 (4): 319-44.
40. Monia BP, Johnston JF, Geiger T et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase (see comments). Nature Med 1996; 2 (6): 668-75.
41. Ivan M, Bond JA, Prat M et al. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14 (20): 2417-23.
42. Zachos G, Spandidos DA. Expression of ras proto-oncogenes: Regulation and implications in the development of human tumors. Crit Rev Oncol Hematol 1997; 26 (2): 65-75.
43. Cioffi CL, Garay M, Johnston JF et al. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol 1997; 51 (3): 383-9.
44. Lau QC, Brusselbach S, Muller R. Abrogation of c-raf expression induces apoptosis in tumor cells. Oncogene 1998; 16 (14): 1899-902.
45. Monia BP. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found Symp 1997; 209: 107-19.
46. Monia BP. First- and second-generation antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies. Anticancer Drug Des 1997; 12 (5): 327-39.
47. Basu A. The potential of protein kinase C as a target for anti-cancer treatment. Pharmacol Ther 1993; 59 (3): 257-80.
48. Ways DK, Kukoly CA, deVente J et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995; 95 (4): 1906-15.
49. Geiger T, Muller M, Dean NM, Fabbro D. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998; 13 (1): 35-45.
50. Dean NM, McKay R. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 91 (24): 11762-6.
51. Dean NM, McKay R, Condon TP, Bennett CF. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994; 269 (23): 16416-24.
52. Dean N, McKay R, Miraglia L et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res 1996; 56 (15): 3499-507.
53. Hockenbery D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348 (6299): 334-6.
54. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52 (19): 5407-11.
55. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87 (1): 265-72.
56. Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large-cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 1996; 88 (3): 1046-51.
57. Pezzella F, Jones M, Ralfkiaer E et al. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992; 65 (1): 87-9.